Krystal Biotech Inc represents values of innovation, dedication, and excellence in the field of biotechnology. The company is committed to developing and delivering advanced gene therapies to treat rare skin diseases. With a vision to transform lives, Krystal Biotech focuses on providing effective and safe solutions that address unmet medical needs. Their corporate philosophy revolves around promoting patient-centric care, scientific rigor, and ethical practices. By leveraging cutting-edge technology and scientific expertise, Krystal Biotech strives to enhance the quality of life for individuals affected by genetic skin disorders.

Krystal Biotech Inc is primarily present in the United States.

Krystal Biotech Inc has achieved several significant milestones. One of the notable achievements includes the successful completion of the phase 2 clinical trial for their gene therapy product, known as KB103. This product aims to treat a rare skin disorder called dystrophic epidermolysis bullosa (DEB). Additionally, the company has also achieved positive results in pre-clinical trials for other gene therapy candidates, showcasing their potential to address various genetic disorders. Krystal Biotech Inc has received several grants and awards for their innovative research and development efforts. These achievements highlight the promising growth and potential of Krystal Biotech Inc in the field of gene therapy.

Krystal Biotech Inc, headquartered in Pittsburgh, Pennsylvania, is a clinical-stage gene therapy company focused on developing and commercializing transformative treatments for patients suffering from rare genetic diseases. Founded in 2015, Krystal Biotech is driven by a mission to deliver potentially curative therapies that address the unmet medical needs of patients worldwide. Leveraging its proprietary Skin TARgeted Delivery platform, the company aims to develop innovative gene therapies for dermatological conditions, starting with its lead product candidate, KB105. Through strategic collaborations, Krystal Biotech strives to revolutionize the treatment landscape by advancing gene therapies to provide hope for patients and their families.

The main competitors of Krystal Biotech Inc in the market include companies such as Regenxbio Inc, bluebird bio Inc, and Sangamo Therapeutics Inc. These companies have a similar focus on gene therapy and are actively engaged in the development and commercialization of innovative treatments for genetic diseases. Krystal Biotech Inc competes with these companies in terms of research, development, and market adoption of gene therapy products.

Krystal Biotech Inc is primarily active in the biotechnology and pharmaceutical industries.

Krystal Biotech Inc is a biopharmaceutical company specializing in gene therapies. Their business model focuses on developing and commercializing innovative treatments to address severe dermatological diseases. By harnessing the power of gene therapy, Krystal Biotech aims to provide targeted and sustainable solutions for patients, offering potential long-term benefits. With a strong emphasis on cutting-edge research and development, they strive to revolutionize the treatment landscape by creating novel therapies that address unmet medical needs. Krystal Biotech Inc's business model is driven by a commitment to scientific excellence and a passion for improving the lives of patients suffering from dermatological conditions.

Raportul Krystal Biotech preț/beneficiu este 66,53.

Raportul Krystal Biotech preț/vânzări este 16,86.

Scorul de calitate AlleAktien pentru Krystal Biotech este 3/10.

Cifra de afaceri a așteptată Krystal Biotech este de 299,62 milioane USD.

Profitul așteptată Krystal Biotech este 75,93 milioane USD.

Krystal Biotech Inc is a biotechnology company focused on developing gene therapy products for rare dermatology and genetic diseases. The company aims to develop innovative therapies that improve the lives of patients with rare diseases. The business model is based on the development and commercialization of gene therapy products. Krystal Biotech uses a proprietary gene therapy platform called HSV-1 vector to develop therapies for serious and rare dermatological conditions such as Epidermolysis bullosa, Netherton syndrome, and Heidelberg syndrome. The company's gene therapy products utilize the HSV-1 vector's ability to introduce DNA into rapidly dividing cells, such as skin cells, to replace the defective gene causing the disease and restore normal functioning of the affected cells. Krystal Biotech focuses on developing gene therapies for severe and rare diseases where effective treatments are often lacking. The company has several gene therapy products in development, including KB103 for the treatment of Epidermolysis bullosa, KB105 for the treatment of Netherton syndrome, and KB104 for the treatment of Heidelberg syndrome. KB103 is currently in phases 1 and 2 of clinical development and has the potential to become the first approved gene therapy product for treating Epidermolysis bullosa. Krystal Biotech also places a strong emphasis on collaboration with other companies and stakeholders in the biotechnology industry. The company has entered into a collaboration agreement with the international pharmaceutical company Bayer to develop a gene therapy platform for the treatment of serious eye diseases. In summary, Krystal Biotech's business model is based on the development and commercialization of gene therapy products for rare dermatological and genetic diseases. The company aims to improve the lives of patients with severe and rare diseases and seeks partnerships and alliances with other biotechnology companies and stakeholders in the industry to achieve this goal.

Krystal Biotech distribuie un dividend de 0 USD în plăți anuale.

Dividenda nu poate fi calculată în prezent pentru Krystal Biotech sau compania nu distribuie dividende.

Codul ISIN pentru Krystal Biotech este US5011471027.

Codul WKN al Krystal Biotech este A2JH2F.

Ticker-ul pentru Krystal Biotech este KRYS.

În ultimele 12 luni, Krystal Biotech a plătit un dividend în valoare de . Aceasta corespunde unei randamente a dividendului de aproximativ . Pentru următoarele 12 luni, Krystal Biotech va plăti probabil un dividend de 0 USD.

Randamentul dividendelor pentru Krystal Biotech este în prezent de .

Krystal Biotech plătește un dividend trimestrial. Acesta este distribuit în lunile .

Krystal Biotech a plătit dividende în fiecare an, în ultimii 0 ani.

Pentru următoarele 12 luni se așteaptă dividende în valoare de 0 USD. Acest lucru corespunde unei randamente a dividendelor de 0 %.

Krystal Biotech este atribuit sectorului 'Sănătate'.

Pentru a primi ultimul dividend de Krystal Biotech de la 01.10.2024 în valoare de 0 USD, trebuia să deții acțiunea în portofoliu înainte de ziua Ex-Tag de pe 01.10.2024.

Ultima plată a dividendului a fost efectuată la 01.10.2024.

În anul 2023, Krystal Biotech a distribuit 0 USD sub formă de dividende.

Dividendele de la Krystal Biotech sunt distribuite în USD.